HyperMelt is an early cancer screening tool that uses microfluidic technology to detect extremely rare tumor-derived DNA from non-invasively collected samples, such as blood.

The highly sensitive digital technology quantifies changes in DNA methylation, an event known to occur early in carcinogenesis. The platform is ideally suited for an early screening tool, since it can obtain information from non-invasively collected samples such as blood and has low cost.

HyperMelt is over 200x more sensitive than the current gold standard in methylation detection, and over 1000x more sensitive than sequencing.